drugset
Drugs / Sebacoyl Dinalbuphine Ester
last change Jun 2026 re-read 3 minutes ago

Sebacoyl Dinalbuphine Ester

also known as SDE · Sebacoyl Dinalbuphine Ester Injection
Developed for
neurological pain disorder · chronic pain syndrome · pain agnosia
Investigated by
Lumosa Therapeutics Co., Ltd. · Dalin Tzu Chi General Hospital

Trials 3

today NCT06344169 · Ph 2/3 NCT02446301 · Ph 1 NCT02468128 · Ph 2/3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02446301 Jan → Apr 2015 neurological pain disorder Lumosa Therapeutics Co., Ltd. Completed No outcome recorded
Phase 2/32 trials · 1 met primary
Phase 2/3 NCT06344169 May 2024 → Mar 2026 overdue chronic pain syndrome Dalin Tzu Chi General Hospital Recruiting No outcome recorded
Phase 2/3 NCT02468128 Dec 2012 → Apr 2015 neurological pain disorder, pain agnosia Lumosa Therapeutics Co., Ltd. Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Sebacoyl Dinalbuphine Ester “Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection” NCT02446301 ↗
2

NCT06344169 ↗

NCT02468128 ↗
Known as SDE “single IM injection of Sebacoyl Dinalbuphine Ester (SDE) injection” NCT02446301 ↗
Known as Sebacoyl Dinalbuphine Ester Injection “Sebacoyl Dinalbuphine Ester Injection” NCT02446301 ↗
Route Intramuscular “Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection” NCT02446301 ↗